{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:32:27Z","timestamp":1790663547249,"version":"4.1.0"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The psychological burden of cutaneous malignant melanoma (CM) is all-encompassing, affecting treatment adherence, recurrence and mortality. However, the prevalence and risk factors of anxiety and depression in CM remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To establish a benchmark pooled prevalence of anxiety and depression in CM, to provide magnitudes of association for clinical, therapeutic and demographic correlates, and to elucidate temporal trends in anxiety and depression from the time of diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review followed the MOOSE guidelines. MEDLINE, Embase, PsychINFO, Web of Science and the Cochrane Library were queried from database inception to 24 August 2023. Study selection, data extraction and quality assessment were performed by two independent authors, utilizing both the Joanna Briggs Institute (JBI) and National Institutes of Health risk-of-bias tools for the latter. The GRADE approach was used to rate the certainty of evidence. Prevalence rates, 95% confidence intervals (CIs) and prediction intervals (PIs) were derived using a random-effects model and estimating between- and within-study variance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine longitudinal and 29 cross-sectional studies were included (7995 patients). Based on the JBI and NIH tools, respectively, quality assessment found 20 and 17 to be at low risk of bias, 12 and 15 to be at moderate risk and 6 and 5 to be at high risk of bias. The prevalence of anxiety [30.6% (95% CI 24.6\u201337.0; PI 18\u201347%)] and depression [18.4% (95% CI 13.4\u201323.9; PI 10\u201333%)] peaked during treatment, declining to pretreatment levels after 1\u2005year [anxiety: 48% vs. 20% (P = 0.005); depression: 28% vs. 13% (P = 0.03)]. Female sex [odds ratio (OR) 1.8, 95% CI 1.4\u20132.3; P &amp;lt; 0.001], age &amp;lt; 60\u2005years (OR 1.5, 95% CI 1.2\u20132.0; P = 0.002) and low educational level (OR 1.5, 95% CI 1.2\u20132.0; P &amp;lt; 0.001) were likely to result in a large increase in the odds of anxiety. Depression was 12.3% higher in those with stage IV vs. those with stage I CM (P = 0.05). Relative to immune checkpoint inhibition, the rates of depression were 22% (P = 0.002) and 34% (P &amp;lt; 0.001) higher among patients with advanced-stage CM receiving interferon-\u03b1 and chemotherapy, respectively. A significant reduction in self-reported depression scores was demonstrated over time (P = 0.003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Notably, anxiety and depression in CM affect women, those younger than 60\u2005years of age and the less educated, with up to 80% higher odds of anxiety in these groups. Anxiety and depression surge during chemotherapy and interferon treatment, especially in advanced CM. Our findings facilitate risk stratification and underscore the need for multidisciplinary vigilance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljae011","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T16:25:34Z","timestamp":1704731134000},"page":"24-35","source":"Crossref","is-referenced-by-count":23,"title":["Prevalence and odds of anxiety and depression in cutaneous malignant melanoma: a proportional meta-analysis and regression"],"prefix":"10.1093","volume":"191","author":[{"given":"Garikai","family":"Kungwengwe","sequence":"first","affiliation":[{"name":"Chelsea and Westminster Hospital, Imperial College Healthcare Trust , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Gowthorpe","sequence":"additional","affiliation":[{"name":"Swansea University Medical School , Swansea , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9917-3432","authenticated-orcid":false,"given":"Stephen R","family":"Ali","sequence":"additional","affiliation":[{"name":"Reconstructive Surgery and Regenerative Medicine Research Group, Swansea University , UK"},{"name":"Welsh Centre for Burns and Plastic Surgery, Morriston Hospital , Swansea , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Warren","sequence":"additional","affiliation":[{"name":"Cardiff University Medical School , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien\u00a0J","family":"Drury","sequence":"additional","affiliation":[{"name":"Welsh Centre for Burns and Plastic Surgery, Morriston Hospital , Swansea , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ky-Leigh","family":"Ang","sequence":"additional","affiliation":[{"name":"Cardiff University Medical School , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7944-8347","authenticated-orcid":false,"given":"John A G","family":"Gibson","sequence":"additional","affiliation":[{"name":"Reconstructive Surgery and Regenerative Medicine Research Group, Swansea University , UK"},{"name":"Welsh Centre for Burns and Plastic Surgery, Morriston Hospital , Swansea , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D","family":"Dobbs","sequence":"additional","affiliation":[{"name":"Reconstructive Surgery and Regenerative Medicine Research Group, Swansea University , UK"},{"name":"Welsh Centre for Burns and Plastic Surgery, Morriston Hospital , Swansea , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-2079","authenticated-orcid":false,"given":"Iain S","family":"Whitaker","sequence":"additional","affiliation":[{"name":"Reconstructive Surgery and Regenerative Medicine Research Group, Swansea University , UK"},{"name":"Welsh Centre for Burns and Plastic Surgery, Morriston Hospital , Swansea , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"2024062015121131900_ljae011-B1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2024062015121131900_ljae011-B2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"2024062015121131900_ljae011-B3","doi-asserted-by":"crossref","first-page":"100024","DOI":"10.1016\/j.lanepe.2021.100024","article-title":"Changing epidemiology and age-specific incidence of cutaneous malignant melanoma in England: an analysis of the national cancer registration data by age, gender and anatomical site, 1981\u20132018","volume":"2","author":"Memon","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"2024062015121131900_ljae011-B4","first-page":"1132","article-title":"Incidence of malignant melanoma of the skin in Norway, 19551989: association with solar ultraviolet radiation, income, and holidays abroad","volume":"2","author":"Graham","year":"1996","journal-title":"Int J Epidemiol"},{"key":"2024062015121131900_ljae011-B5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10552-005-3637-4","article-title":"Trends for in-situ and invasive melanoma in Queensland, Australia, 1982\u20132002","volume":"17","author":"Coory","year":"2006","journal-title":"Cancer Causes Control"},{"key":"2024062015121131900_ljae011-B6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2024062015121131900_ljae011-B7","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"2024062015121131900_ljae011-B8","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"2024062015121131900_ljae011-B9","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"2024062015121131900_ljae011-B10","doi-asserted-by":"crossref","first-page":"100050","DOI":"10.1016\/j.esmoop.2021.100050","article-title":"A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma","volume":"6","author":"Tarhini","year":"2021","journal-title":"ESMO Open"},{"key":"2024062015121131900_ljae011-B11","first-page":"353","article-title":"Perceived well-being in malignant melanoma survivors","volume":"16","author":"Dirksen","year":"1989","journal-title":"Oncol Nurs Forum"},{"key":"2024062015121131900_ljae011-B12","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/pon.6184","article-title":"Psychological and behavioral symptoms in patients with melanoma: a systematic review and meta-analysis","volume":"32","author":"Danielsen","year":"2023","journal-title":"Psychooncology"},{"key":"2024062015121131900_ljae011-B13","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/archdermatol.2009.308","article-title":"Psychological responses and coping strategies among patients with malignant melanoma","volume":"145","author":"Kasparian","year":"2009","journal-title":"Arch Dermatol"},{"key":"2024062015121131900_ljae011-B14","author":"Gowthorpe"},{"key":"2024062015121131900_ljae011-B15","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"2024062015121131900_ljae011-B16","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Lefebvre","year":"2023"},{"key":"2024062015121131900_ljae011-B17","doi-asserted-by":"crossref","first-page":"103919","DOI":"10.1016\/j.critrevonc.2023.103919","article-title":"Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: a systematic scoping review","volume":"183","author":"Egeler","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2024062015121131900_ljae011-B18","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders: DSM-5\u2122","author":"American Psychiatric Association, DSM-5 Task Force","year":"2013"},{"key":"2024062015121131900_ljae011-B19","author":"World Health Organization"},{"key":"2024062015121131900_ljae011-B20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.15171\/ijhpm.2014.71","article-title":"The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence","volume":"3","author":"Munn","year":"2014","journal-title":"Int J Health Policy Manag"},{"key":"2024062015121131900_ljae011-B21","author":"National Heart, Lung, and Blood Institute"},{"key":"2024062015121131900_ljae011-B22","doi-asserted-by":"crossref","first-page":"e037324","DOI":"10.1136\/bmjopen-2020-037324","article-title":"Comparison of risk-of-bias assessment approaches for selection of studies reporting prevalence for economic analyses","volume":"10","author":"Glasgow","year":"2020","journal-title":"BMJ Open"},{"key":"2024062015121131900_ljae011-B23","author":"Dattani"},{"key":"2024062015121131900_ljae011-B24","first-page":"9","article-title":"Practical issues in calculating the sample size for prevalence studies","volume-title":"Arch Orofac Sci","author":"Naing","year":"2006"},{"key":"2024062015121131900_ljae011-B25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","article-title":"A new improved graphical and quantitative method for detecting bias in meta-\u00adanalysis","volume":"16","author":"Furuya-Kanamori","year":"2018","journal-title":"Int J Evid Based Healthc"},{"key":"2024062015121131900_ljae011-B26","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2024062015121131900_ljae011-B27","doi-asserted-by":"crossref","first-page":"h870","DOI":"10.1136\/bmj.h870","article-title":"Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients","volume":"350","author":"Iorio","year":"2015","journal-title":"BMJ"},{"key":"2024062015121131900_ljae011-B28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic I2 can be biased in small meta-analyses","volume":"15","author":"von Hippel","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"2024062015121131900_ljae011-B29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/jrsm.1230","article-title":"Basics of meta-\u00adanalysis: I2 is not an absolute measure of heterogeneity","volume":"8","author":"Borenstein","year":"2017","journal-title":"Res Synth Methods"},{"key":"2024062015121131900_ljae011-B30","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s11764-020-00885-9","article-title":"Anxiety and depression after diagnosis of high-risk primary cutaneous melanoma: a 4-year longitudinal study","volume":"14","author":"Beesley","year":"2020","journal-title":"J Cancer Surviv"},{"key":"2024062015121131900_ljae011-B31","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0959-8049(94)00333-Z","article-title":"Psychological reactions in patients with malignant melanoma","volume":"31","author":"Brandberg","year":"1995","journal-title":"Eur J Cancer"},{"key":"2024062015121131900_ljae011-B32","first-page":"466","article-title":"Dose-dependent development of depressive symptoms during adjuvant interferon-alpha treatment of patients with malignant melanoma","volume":"51","author":"Friebe","year":"2010","journal-title":"Psychosomatics"},{"key":"2024062015121131900_ljae011-B33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s12253-014-9777-7","article-title":"Psychological changes in melanoma patients during ipilimumab treatment compared to low-dose interferon alpha therapy \u2013 a follow-up study of first experiences","volume":"20","author":"Kov\u00e1cs","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"2024062015121131900_ljae011-B34","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.21.02488","article-title":"Clinical outcomes and risk stratification of early-stage melanoma micrometastases from an international multicentre study: implications for the management of American Joint Committee on Cancer IIIA Disease","volume":"40","author":"Moncrieff","year":"2022","journal-title":"J Clin Oncol"},{"key":"2024062015121131900_ljae011-B35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11136-004-1694-x","article-title":"Validation of the FACT-BRM with interferon-alpha treated melanoma patients","volume":"14","author":"Paterson","year":"2005","journal-title":"Qual Life Res"},{"key":"2024062015121131900_ljae011-B36","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1007\/s00520-019-05168-3","article-title":"Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study","volume":"28","author":"Rogiers","year":"2020","journal-title":"Support Care Cancer"},{"key":"2024062015121131900_ljae011-B37","doi-asserted-by":"crossref","first-page":"2192480","DOI":"10.1155\/2020\/2192480","article-title":"Neurocognitive function, psychosocial outcome, and health-related quality of life of the first-generation metastatic melanoma survivors treated with ipilimumab","volume":"2020","author":"Rogiers","year":"2020","journal-title":"J Immunol Res"},{"key":"2024062015121131900_ljae011-B38","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbi.2004.02.002","article-title":"Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha","volume":"18","author":"Schaefer","year":"2004","journal-title":"Brain Behav Immun"},{"key":"2024062015121131900_ljae011-B39","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/pon.3238","article-title":"Self-efficacy for coping with cancer in melanoma patients: its association with physical fatigue and depression","volume":"22","author":"Albrecht","year":"2013","journal-title":"Psychooncology"},{"key":"2024062015121131900_ljae011-B40","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/pon.3718","article-title":"Supportive care needs, anxiety, depression and quality of life amongst newly diagnosed patients with localised invasive cutaneous melanoma in Queensland, Australia","volume":"24","author":"Beesley","year":"2015","journal-title":"Psychooncology"},{"key":"2024062015121131900_ljae011-B41","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/02841860310021518","article-title":"Anxiety and depressive symptoms measured by the Hospital Anxiety and Depression Scale as predictors of time to recurrence in localized cutaneous melanoma","volume":"43","author":"Bergenmar","year":"2004","journal-title":"Acta Oncol"},{"key":"2024062015121131900_ljae011-B42","doi-asserted-by":"crossref","first-page":"e0116440","DOI":"10.1371\/journal.pone.0116440","article-title":"Depression, anxiety and quality of life in long-term survivors of malignant melanoma: a register-based cohort study","volume":"10","author":"Beutel","year":"2015","journal-title":"PLOS ONE"},{"key":"2024062015121131900_ljae011-B43","first-page":"258","article-title":"Psychosocial burden and subjective experience of melanoma patients in the ambulant follow-up","volume":"53","author":"Blum","year":"2003","journal-title":"Psychother Psychosom Med Psychol"},{"key":"2024062015121131900_ljae011-B44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/0284186X.2020.1818823","article-title":"Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls","volume":"60","author":"Boekhout","year":"2021","journal-title":"Acta Oncol"},{"key":"2024062015121131900_ljae011-B45","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/0284186X.2018.1557344","article-title":"Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood","volume":"58","author":"B\u00f8hn","year":"2019","journal-title":"Acta Oncol"},{"key":"2024062015121131900_ljae011-B46","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1037\/hea0000766","article-title":"A comparison of posttraumatic growth changes in breast cancer and melanoma","volume":"38","author":"Bourdon","year":"2019","journal-title":"Health Psychol"},{"key":"2024062015121131900_ljae011-B47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/pon.2960010204","article-title":"Anxiety and depressive symptoms at different stages of malignant melanoma","volume":"1","author":"Brandberg","year":"1992","journal-title":"Psychooncology"},{"key":"2024062015121131900_ljae011-B48","first-page":"540","article-title":"Anxiety, posttraumatic stress, and fear of cancer progression in patients with melanoma in cancer aftercare","volume":"36","author":"Erim","year":"2013","journal-title":"Onkologie"},{"key":"2024062015121131900_ljae011-B49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2016.11.017","article-title":"The risk of being depressed is significantly higher in cancer patients than in the general population: prevalence and severity of depressive symptoms across major cancer types","volume":"72","author":"Hartung","year":"2017","journal-title":"Eur J Cancer"},{"key":"2024062015121131900_ljae011-B50","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/CJI.0b013e3181b8bdb9","article-title":"Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial","volume":"33","author":"Heinze","year":"2010","journal-title":"J Immunother"},{"key":"2024062015121131900_ljae011-B51","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/07347332.2018.1499691","article-title":"Predictors of quality of life in melanoma patients 4\u2005years after diagnosis: results of a nationwide cohort study in Germany","volume":"36","author":"Krajewski","year":"2018","journal-title":"J Psychosoc Oncol"},{"key":"2024062015121131900_ljae011-B52","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/annonc\/mdi146","article-title":"Predictors of quality of life in newly diagnosed melanoma and breast cancer patients","volume":"16","author":"Lehto","year":"2005","journal-title":"Ann Oncol"},{"key":"2024062015121131900_ljae011-B53","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ejca.2015.01.007","article-title":"Prospective evaluation of follow-up in melanoma patients in Germany \u2013 results of a multicentre and longitudinal study","volume":"51","author":"Livingstone","year":"2015","journal-title":"Eur J Cancer"},{"key":"2024062015121131900_ljae011-B54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000007987","article-title":"The need for psycho-\u00adoncological support for melanoma patients","volume":"96","author":"Mayer","year":"2017","journal-title":"Medicine"},{"key":"2024062015121131900_ljae011-B55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/120347540300700602","article-title":"Characterizing anxiety in melanoma patients","volume":"7","author":"Missiha","year":"2003","journal-title":"J Cutan Med Surg"},{"key":"2024062015121131900_ljae011-B56","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdu366","article-title":"Prevalence and correlates of unmet supportive care needs in patients with resected invasive cutaneous melanoma","volume":"25","author":"Molassiotis","year":"2014","journal-title":"Ann Oncol"},{"key":"2024062015121131900_ljae011-B57","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13651501.2017.1301482","article-title":"Psychiatric comorbidity and suicidal ideation in psoriasis, melanoma and allergic disorders","volume":"21","author":"Pompili","year":"2017","journal-title":"Int J Psychiatry Clin Pract"},{"key":"2024062015121131900_ljae011-B58","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1188\/05.ONF.661-667","article-title":"Nutritional, functional, and emotional characteristics related to fatigue in patients during and after biochemotherapy","volume":"32","author":"Porock","year":"2005","journal-title":"Oncol Nurs Forum"},{"key":"2024062015121131900_ljae011-B59","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1684\/ejd.2019.3523","article-title":"Comparison of quality of life between melanoma and non-melanoma skin cancer patients","volume":"29","author":"Sampogna","year":"2019","journal-title":"Eur J Dermatol"},{"key":"2024062015121131900_ljae011-B60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF00435223","article-title":"The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique","volume":"2","author":"Sigurdardottir","year":"1993","journal-title":"Qual Life Res"},{"key":"2024062015121131900_ljae011-B61","first-page":"369","article-title":"Assessment of anxiety and depression status in Turkish cutaneous melanoma patients","volume":"18","author":"Tas","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"key":"2024062015121131900_ljae011-B62","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CMR.0000000000000348","article-title":"Psychological characteristics of early-stage melanoma patients: a cross-sectional study on 204 patients","volume":"27","author":"Tesio","year":"2017","journal-title":"Melanoma Res"},{"key":"2024062015121131900_ljae011-B63","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s11136-017-1532-6","article-title":"Comparison of quality of life among long-term melanoma survivors and non-melanoma controls: a cross-sectional study","volume":"26","author":"Vogel","year":"2017","journal-title":"Qual Life Res"},{"issue":"Suppl. 1","key":"2024062015121131900_ljae011-B64","first-page":"53","article-title":"Psychological status and coping with illness in patients with malignant melanoma","volume":"31","author":"Vurnek","year":"2007","journal-title":"Coll Antropol"},{"key":"2024062015121131900_ljae011-B65","doi-asserted-by":"crossref","first-page":"e12901","DOI":"10.1111\/ecc.12901","article-title":"Fear of cancer progression in patients with stage IA malignant melanoma","volume":"27","author":"Wagner","year":"2018","journal-title":"Eur J Cancer Care (Engl"},{"key":"2024062015121131900_ljae011-B66","doi-asserted-by":"crossref","first-page":"880978","DOI":"10.3389\/fpsyt.2022.880978","article-title":"Fear of progression, anxiety, and depression in patients with advanced melanoma in the COVID-19 and post-COVID-19 era","volume":"13","author":"Wang","year":"2022","journal-title":"Front Psychiatry"},{"issue":"Suppl. 2","key":"2024062015121131900_ljae011-B67","first-page":"75","article-title":"Psychological status and illness perceptions in patients with melanoma","volume":"32","author":"Zivkovic","year":"2008","journal-title":"Coll Antropol"},{"key":"2024062015121131900_ljae011-B68","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12874-021-01381-z","article-title":"Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence","volume":"21","author":"Barker","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"2024062015121131900_ljae011-B69","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1007\/s00520-021-06046-7","article-title":"Cross-sectional study of sex differences in psychosocial quality of life of long-term melanoma survivors","volume":"29","author":"Vogel","year":"2021","journal-title":"Support Care Cancer"},{"key":"2024062015121131900_ljae011-B70","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jpsychires.2011.03.006","article-title":"Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness","volume":"45","author":"McLean","year":"2011","journal-title":"J Psychiatr Res"},{"key":"2024062015121131900_ljae011-B71","first-page":"247","volume-title":"Childhood and Society","author":"Erikson EH. Eight ages of man. In","year":"1993"},{"key":"2024062015121131900_ljae011-B72","first-page":"1","article-title":"Fear of cancer recurrence or progression: what is it and what can we do about it?","volume":"42","author":"Bergerot","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2024062015121131900_ljae011-B73","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1200\/JCO.2016.68.2278","article-title":"Psychoeducational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma: results of a randomized controlled trial","volume":"34","author":"Dieng","year":"2016","journal-title":"J Clin Oncol"},{"key":"2024062015121131900_ljae011-B74","author":"All.Can UK"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae011\/57055196\/ljae011.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/1\/24\/58289377\/ljae011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/1\/24\/58289377\/ljae011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T11:29:20Z","timestamp":1718882960000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/1\/24\/7514006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,10]]},"published-print":{"date-parts":[[2024,6,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae011","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,1,10]]}}}